Adial Pharmaceuticals, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Adial Pharmaceuticals, Inc. (ADIL) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$2.46 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2024-08-13
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$2.46M.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$1.90M.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was -$1.35M.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$1.51M.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$7.00M.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$10.80M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$2.46M 10-Q · filed 2024-08-13 | -$8.93M 10-Q · filed 2024-08-13 | ||
| 2023-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$3.25M derived: sum of 2 quarters · filed 2024-04-01 | -$4.76M derived: sum of 3 quarters · filed 2024-08-13 | -$7.00M 10-K · filed 2024-04-01 |
| 2023-09-30 | -$1.35M 10-Q · filed 2023-11-14 | -$2.86M derived: sum of 2 quarters · filed 2024-08-13 | -$5.10M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$1.51M 10-Q · filed 2024-08-13 | -$3.75M 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$5.10M derived: sum of 2 quarters · filed 2024-04-01 | -$8.34M derived: sum of 3 quarters · filed 2024-04-01 | -$10.80M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$2.55M 10-Q · filed 2023-11-14 | -$5.79M derived: sum of 2 quarters · filed 2023-11-14 | -$8.25M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$3.24M 10-Q/A · filed 2023-10-30 | -$5.70M 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |